| UNITED STATES | ||
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 |
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER
SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION
OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 001-39387
Renalytix plc |
| (Exact name of registrant as specified in its charter) |
| 2 Leman
Street, London E1W 9US, United Kingdom; Tel: +44 20 3139 2910
|
| (Address,including zip code, and telephone number, including area code, of registrant’s principal executive offices) |
| American Depository Shares (each representing two shares of ordinary stock, nominal
value £0.0025 per share) Ordinary Shares, nominal value £0.0025 per share |
| (Title of each class of securities covered by this Form) |
| |
| (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains) |
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
| Rule 12g-4(a)(1) | ☒ | ||
| Rule 12g-4(a)(2) | ☐ | ||
| Rule 12h-3(b)(1)(i) | ☒ | ||
| Rule 12h-3(b)(1)(ii) | ☐ | ||
| Rule 15d-6 | ☐ | ||
| Rule 15d-22(b) | ☐ |
Approximate number of holders of record as of the certification or notice date: 157
Pursuant to the requirements of the Securities Exchange Act of 1934 (Name of registrant as specified in charter) has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
| Date: July 30, 2025 | By: | /s/ James McCullough |
| Name: | James McCullough | |
| Title: | Chief Executive Officer |